GE Healthcare Life Sciences releases software for cell therapy workflow
Chicago, Illinois - Dec 2, 2019 (PRN):
GE Healthcare Life Sciences continues to build out its flexible solutions across the cell therapy workflow with the commercial availability of SpinOculation C-Pro Protocol Software. Part of the Sepax™ C-Pro Cell Processing System, the software closes and automates the cell transduction step. When used in combination with the Sepax C-Pro instrument and CT-60.1 single-use kit, the software enables users to choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences, said: “Cell therapy manufacturing is complex and requires advanced technologies. GE Healthcare Life Sciences continues to invest and develop the digital solutions needed to advance cell and gene therapies. The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next generation therapeutics.”
Additionally, the SpinOculation C-Pro Protocol helps users:
Gain reproducibility in transduction steps with an automated and closed solution
The SpinOculation C-Pro application software is available worldwide.
About GE Healthcare Life Sciences
GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.
Information from Press Release Network may be freely distributed to any publication. Wherever applicable, please cite Press Release Network as the news source.
DISCLAIMER: The content of each press release is the responsibility of the publishing organisation and is not vetted or approved by Press Release Network prior to publication. Press Release Network is not liable directly or indirectly for any direct or consequential loss, damage or expense resulting from the material disseminated and published on the site. Subscribers are advised to check the accuracy of all press releases and to obtain their own professional advice in relation to such information.